Research Analysts Offer Predictions for VRCA Q2 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities researchers at Brookline Capital Management increased their Q2 2025 earnings estimates for Verrica Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 14th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($0.07) for the quarter, up from their previous estimate of ($0.08). The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals’ Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.26) EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of $3.44 million for the quarter, compared to analysts’ expectations of $2.53 million.

Several other equities research analysts have also weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reiterated a “neutral” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Verrica Pharmaceuticals Stock Up 3.2%

VRCA opened at $0.66 on Monday. The firm has a market cap of $61.26 million, a price-to-earnings ratio of -0.36 and a beta of 1.73. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $9.40. The company’s 50-day moving average price is $0.51 and its 200 day moving average price is $0.69.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Verrica Pharmaceuticals by 23.3% in the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock valued at $61,000 after purchasing an additional 26,308 shares during the period. AQR Capital Management LLC increased its stake in shares of Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock valued at $26,000 after purchasing an additional 44,275 shares during the period. Kovitz Investment Group Partners LLC acquired a new stake in shares of Verrica Pharmaceuticals in the first quarter valued at approximately $45,000. Invesco Ltd. increased its stake in shares of Verrica Pharmaceuticals by 64.8% in the first quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock valued at $33,000 after purchasing an additional 29,256 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Verrica Pharmaceuticals by 127.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock valued at $44,000 after purchasing an additional 55,852 shares during the period. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.